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Abstract
The modern intensive care unit (ICU) has evolved into an area where mortality and morbidity
can be reduced by identification of unexpected hemodynamic and ventilatory
decompensations before long-term problems result. Because intensive care physicians are
caring for an increasingly heterogeneous population of patients, the indications for
aggressive monitoring and close titration of care have expanded. Agitated patients are
proving difficult to deal with in nonmonitored environments because of the unpredictable
consequences of the agitated state on organ systems. The severe agitation state that is
associated with ethanol withdrawal and delirium tremens (DT) is examined as a model for
evaluating the efficacy of the ICU environment to ensure consistent stabilization of potentially
life-threatening agitation and delirium.
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Introduction
The major etiology of integrative brain failure is a hemody-
namic or metabolic decompensation elsewhere in the body
[1•]. The ICU environment provides a repository of typical
predisposing factors of a hemodynamic or metabolic
nature, including acute or chronic organic brain vascular
insufficiency, endocrine insufficiency, acute or chronic car-
diopulmonary decompensations, multiorgan system insuffi-
ciency, relative hypoxia, poor tissue perfusion,
multimedications, and, finally, sleep–wake cycle disruption
caused by immobilization, anxiety and pain [2]. Clinical
signs of agitation are likely to be produced when there is
integrative brain failure plus an intense source of sensory
stimuli [3]. Environmental stress, although likely to exacer-
bate integrative brain failure, is rarely a precipitating cause
by itself [4]. When agitation accompanies brain failure in a
critical care setting, a failure to integrate cerebral function-
ing exists, and this constitutes a true emergency.
Agitation is a visual clue that disintegration of normal
motor axis integration is occurring, with mischanneling of
incoming sensory stimuli [5•]. There is growing consensus
that delirium is a manifestation of cerebral insufficiency,
both generalized and focal, that is accompanied by dys-
regulation of neurotransmitter systems. Short circuits into
phylogenetically old brain areas such as basal ganglia,
reticular formation, vestibular nuclei, and often the red
nucleus (extrapyramidal system) produce the clinical
picture of uncoordinated and nonpurposeful movements
[6•]. Delirium is characterized by global disorders of cogni-
tion and wakefulness, and by impairment of psychomotor
behavior. Major cognitive functions such as perception,
deductive reasoning, memory, attention and orientation
are all globally disordered. Excessive motor activity fre-
quently accompanies severe cases of delirium and, when
this occurs, the resulting constellation of symptoms is
called ‘agitated delirium’.Critical Care    Vol 4 No 2 Crippen
Generally, such episodes are indicated by escalating agi-
tation in the face of increasing sedative administration and
the addition of multiple drugs. Eventually, a point is
reached at which the underlying causes of agitation, com-
bined with side effects of pharmacologic agents, threaten
respiratory and hemodynamic stability. The mortality of
severe delirium has been exacerbated in the past by respi-
ratory failure brought on by sedative side effects in the
absence of adequate monitoring [7••]. Clearly, administra-
tion of escalating doses of antiagitation medications signal
a serious problem that must be aggressively evaluated. Ini-
tially, a rapid evaluation to determine or exclude the pres-
ence of disorders brought about by medical or surgical
decompensations should be a priority. This is the main
reason why the patient is in the ICU, attached to sophisti-
cated monitoring devices. Emergent airway decompensa-
tions can rapidly be ruled out by capnography [8]. Acute
cardiac decompensations can rapidly be detected by con-
tinuous mixed venous oximetry, and acute hypoxia by con-
tinuous pulse oximetry. Most of these devices are
equipped with alarms that signal exceeded parameters
before actual hemodynamic decompensation occurs. After
ruling out emergent medical/surgical decompensations,
the somatic effects of unrelenting agitation should be
quickly and effectively blunted [9••]. This will facilitate the
search for the underlying etiology without concurrent end-
organ impairment.
A model for life-threatening agitation: ethanol
withdrawal
Beverages that contain the short-acting central nervous
system (CNS) depressant ethanol are commonly imbibed
throughout the world. One might argue that most people
imbibe more or less responsibly, because somewhere in
their brain resides a switch that is sensitive to accumulat-
ing effects of ethanol, such as vertigo and nausea. When
those effects appear, the switch is activated and a signal
to stop drinking appears. There is another population of
imbibers in whom such a switch is attenuated or missing,
however. This population could be called ‘career drinkers’
and they drink continuously through the day and night,
bathing their brain in a continuous flow of ethanol. This
population is somewhat separate from the group referred
to as ‘alcoholics’, whose addiction commonly presents as
social problems rather than as the rote ethanol intake
throughout their day. Alcoholic persons are considered to
carry that diagnosis whether they drink frequently, binge
drink or do not drink at all.
The CNS function of a career drinker rapidly becomes
dependent on the depressive effects of ethanol, and the
action of appropriate neuroreceptors are downregulated
[10]. Once dependence occurs, the effect extends to
other chemical CNS depressants with similar actions,
such as benzodiazepines and barbiturates (cross-depen-
dence) [11]. Tolerance to alcohol also occurs as a result
of the body’s ability to effectively deactivate the drug as a
consequence of repeated exposure. Accordingly, higher
doses of replacement cross-dependent depressants such
as benzodiazepines are sometimes required to equal the
various pharmacodynamic effects of alcohol (cross-toler-
ance) [12]. Withdrawal symptoms, manifested by the
sudden decompensation of neuroreceptors, occur after
the rapid ebb of CNS depressant drugs that saturate the
brain, especially those that have a short duration of action
(ie ethanol). Ethanol withdrawal symptoms can be amelio-
rated with similar, but longer acting cross-dependent CNS
depressant drugs, allowing the withdrawal period to be
effectively lengthened and attenuated and avoiding rapid
fluctuations [13•]. CNS active drugs that achieve depen-
dence are more potent than similar substances, however, so
the process of substituting cross-dependent drugs to reset
neurotransmitters does not proceed as effectively [14].
The benzodiazepines have similar side effects and compli-
cations. They tend to potentiate the analgesic effect of
opiates and increase the incidence of sudden, unexpected
hypotension and respiratory depression. All benzodi-
azepines reduce the ventilatory response to hypoxia.
When given in continuous infusion, however, relatively
large doses (in the order of 100–150mg/kg) are required
to produce clinically important respiratory depression
[15•]. It is of the utmost importance that respiratory and
hemodynamic function is monitored during the infusion of
any benzodiazepine, and that the proper technology is
readily available to treat sudden, unexpected decompen-
sations. The traditional choice of house-staff for the treat-
ment of DT, as espoused by the Washington Manual of
Medical Therapeutics [16], has been the first-generation
sedatives chlordiazepoxide and diazepam. In current prac-
tice, these drugs have been essentially superseded by
second-generation sedatives that are more titratable and
have fewer long-acting intermediaries. Diazepam is effec-
tive for initial control of severe symptoms, and especially
for withdrawal seizures. Diazepam and chlordiazepoxide
are difficult to administer in a continuous infusion, and so
cannot be titrated effectively to treat the unstable and fluc-
tuating constellation of DT symptoms effectively.
Ethanol withdrawal and delirium tremens
DT is a severe neuronal hyperexcitation syndrome that
occurs following abrupt cessation of alcohol consumption
[17]. Classic DT, in comparison with other related alcohol
withdrawal states such as alcoholic hallucinosis and minor
alcohol withdrawal, is characterized by a marked increase
in motor and autonomic activity [18]. Pronounced physical
dependence on alcohol and marked physical withdrawal
signs (seizures, hypertension, hyperthermia, tachycardia,
tachypnea) are the characteristic pathophysiologic fea-
tures that indicate the severity of DT. Withdrawal symp-
toms result from a compensatory increase in the activity of
excitatory mechanisms (upregulation) involving the neuro-http://ccforum.com/content/4/2/081
transmitters norepinephrine, dopamine, and the N-methyl-
D-aspartate (NMDA) receptor, and diminished activity
(downregulation) of the inhibitory receptors g-aminobutyric
acid (GABA)-A and a2-adrenoceptors, after prolonged
depression of the CNS by ethanol [19]. It has been
hypothesized that physical withdrawal signs (tremor,
hypertension, tachycardia, autonomic hyperactivity) are
determined by the degree of physical dependence devel-
oped during the most recent drinking period, whereas the
psychotic signs (misperceptions, hallucinations, and
seizures) result from accumulated CNS hyperactivity
developed over many years of repeated alcohol intoxica-
tion and withdrawal [20•]. Once developed, DT is mani-
fested by an unpredictable, volatile and fluctuating clinical
course of agitation. Because of the phenomena of cross-
dependence and cross-tolerance, conventional approaches
utilizing sedatives such as benzodiazepines and barbitu-
rates may require a high dosage regimen, which can pre-
cipitate hemodynamic and ventilatory depression well
before the physiologic manifestations associated with
delirium can be brought under control.
Treating ethanol withdrawal: general principles
The effectiveness of treatment for DT and related states
depends largely on the ability of the chosen drug to sub-
stitute for alcohol in the variety of its actions on the CNS.
It has been shown [21] that the GABA-gated and gluta-
mate-gated ion channels are the molecular sites of alcohol
effect. Glutamic acid has an established role as the major
excitatory amino acid neurotransmitter in the CNS, mediat-
ing fast excitatory postsynaptic potentials in the brain [22].
At least three different types of glutamate receptors have
been discovered and named for the agonists that activate
them: kainate, quisqualate, and NMDA. Ethanol has been
shown to inhibit NMDA-activated currents in mammalian
neurons over a concentration range that produces intoxi-
cation. Ethanol is thought to inhibit the NMDA-activated
ion current by a novel type of interaction with a hydropho-
bic site that is associated with the NMDA channel. Kainate
and quisqualate channels appear to be blocked only by
higher alcohol concentrations that clinically produce seda-
tion, stupor and coma in humans, suggesting that inhibi-
tion of these receptors is associated with the anesthetic
properties of ethanol.
GABA is an important inhibitory neurotransmitter in the
mammalian CNS. Two major types of GABA receptors
(GABA-A and GABA-B) have been identified, on the basis
of the selectivity of agonists/antagonists and coupling
mechanisms. GABA-gated ion channels mediate pre-
synaptic inhibition in the spinal cord and fast inhibitory
postsynaptic potentials in the CNS [23]. GABA-A recep-
tor-mediated transmission has been shown [24•] to be
facilitated by alcohol, benzodiazepines, and barbiturates.
Therefore, ethanol appears to have a pharmacodynamic
profile similar to that of the sedative–hypnotic classes of
drugs, such as benzodiazepines and barbiturates, which
enhance GABAergic transmission in the mammalian CNS
[25]. Chronic alcohol consumption results in upregulation
of the GABA-binding sites, implicating a potential role of
these changes in alcohol tolerance and withdrawal [26].
Prolonged presence of alcohol–GABA agonist in the brain
appears to produce a relative ‘deficiency’ of GABA in the
CNS that is due to the upregulation of receptors, and pos-
sibly due to the involvement of other negative feedback
mechanisms.
On the other hand, downregulation of NMDA, kainate, and
quisqualate receptors is most likely to induce a state of
CNS hyperexcitability that involves different neuronal
pools and reverberating circuits [27]. Depression and
diminished function of a2-autoadrenoreceptors have been
implicated in the adrenergic hyperactivity that occurs
during alcohol withdrawal [28]. Reduced level of
dopamine activity has also been shown to be associated
with the acute withdrawal states [29]. It has therefore
been hypothesized [30] that alcoholic delirium may be
directly related to the reduced level of central dopaminer-
gic activity. Central anticholinergic properties of ethanol
may contribute significantly to the psychotic and physical
withdrawal signs. Physostigmine, a short-acting
cholinesterase inhibitor, has been shown [31] to be effec-
tive in the prevention of development of DT. Ethanol, ben-
zodiazepines, and barbiturates are CNS depressants,
producing dose-dependent sedation and expressing
cross-dependence and cross-tolerance. Based on their
GABA-mimetic actions, drugs that exhibit similar pharma-
codynamic profiles are benzodiazepines and barbiturates.
Each of these drugs might substitute for alcohol in physi-
cally dependent individuals.
Benzodiazepines are currently the most commonly used
drugs to provide prophylaxis and treatment of DT, and
large doses may be required to produce anxiolysis and
sedation in physically dependent patients [32]. Although
benzodiazepines are efficient GABA agonists, they do not
seem to cross-react with the glutamatergic system in the
CNS as alcohol does. This lack of equipotency may
explain the ineffectiveness of benzodiazepines in control-
ling agitation in DT, even when exceedingly high doses of
benzodiazepines are used. Inhibition of kainate and
quisqualate receptor-mediated responses have been
implicated in the general anesthetic properties of ethanol,
and have also been observed in barbiturates [33].
Because of this additional reaction with glutamate recep-
tor mechanisms, barbiturates appear to be closer to the
neurochemical effects of alcohol than are benzodi-
azepines, but exhibit more clinical side effects.
Treating delirium tremens: sedative therapy
The general approach to the treatment of physical drug
dependency is the substitution of the drug that has beenabused with another one that has a similar pharmacologic
profile. Following such a substitution of a cross-dependent
substance, weaning (resetting neurotransmission) pro-
ceeds in a more predictable and titrated manner [34]. The
effective treatment of ethanol withdrawal depends greatly
on when the symptoms are recognized for what they are. It
is not uncommon for career drinkers to fool family and
friends into believing they are merely ‘social drinkers’. The
difference is that they drink socially 18 h a day. Thus,
when they fall and break their hip and land in a hospital,
there may not be a history of serious drinking. When the
patient begins to exhibit withdrawal symptoms, it may be
misdiagnosed for a fairly long period of time, during which
the symptomatology may inexorably proceed to the ‘storm
phase’. The first course of action should be the administra-
tion of a cross-dependent sedative, in doses that are
titrated to achieve control of the patient with a minimum of
obfuscating side effects. As the severity of the disease
progresses, rapid changes in restlessness necessitate the
choice of a drug with a rapid titratability, adjusting levels of
sedation to the prevalent state of CNS excitation.
There is little current rationale for the use of chlordiazepox-
ide or diazepam in the treatment of ethanol withdrawal.
They each have a number of long-acting intermediaries,
they cannot be reliably given intravenously, and they
cannot be used in a continuous infusion and so cannot be
titrated effectively to the unstable and fluctuating constel-
lation of DT symptoms.
Lorazepam is an intermediate to long-acting benzodi-
azepine with typical anxiolytic and sedative qualities [35].
The drug has a mild amnestic effect as well. Lorazepam
4mg is about equivalent to 10mg diazepam [36]. Interme-
diary products do not accumulate and metabolism does
not require hepatic oxidative metabolism; it only requires
glucuronidation, which makes it an attractive drug in liver
insufficiency. Lorazepam has been approved for oral, intra-
muscular, and intravenous use, and the traditional dose for
patients in the ICU has been 1–2mg every 3–4 h.
Midazolam is a short-acting CNS depressant. Midazolam
is relatively water soluble compared with other benzodi-
azepines, increasing the rapidity of its action [37]. The
potency of midazolam is about three to four times that of
diazepam, and it has a shorter elimination half-life of
1.5–3.5 h. Sedation after intravenous injection is achieved
within 1–5 min, with a duration of action of less than 2 h
[38]. The treatment for noradrenergic-induced panic and
anxiety differs radically from that of similar symptoms
induced by heart failure. Midazolam is uniquely practical in
the ICU environment because its rapid-acting/short dura-
tion properties allow its use as a continuous titrated infu-
sion [39]. This makes midazolam useful for titrated
sedation, anxiolysis, and anterograde amnesia in the con-
scious, restless patient with unstable hemodynamics.
There is a relatively wide margin of safety when midazolam
is administered by continuous infusion in the ICU setting,
where facilities are available for appropriate monitoring [40].
Psychoactive drugs in the major tranquilizer class may
aggravate alcohol withdrawal states by several mecha-
nisms. First, phenothiazines have been shown to enhance
norepinephrine release from the cerebral cortex of experi-
mental animals, and to antagonize the action of clonidine
on a2-autoreceptors. Second, there is a possibility of trig-
gering the malignant neuroleptic syndrome in predisposed
hyperthermic patients. Third, several well-controlled trials
have clearly documented an aggravating effect of neu-
roleptics on physical withdrawal signs, precipitating
seizures and increasing mortality rate [41]. Therefore, on
the basis of existing evidence suggesting detrimental
effects in different phases of alcohol withdrawal states,
major tranquilizers should be excluded from the treatment
of DT. It should, however, be noted that there are refer-
ences that suggest that neuroleptics can be useful in low
doses, especially in combination with benzodiazepines for
lower levels of DT [42].
Neuroleptic butryphenones such as haloperidol seem to be
beneficial in the treatment of restlessness and aggressive
agitation by reordering dopamine neurotransmission, espe-
cially in combination with benzodiazepines [43]. Haloperi-
dol appears to exert a diffuse depressive effect at the
subcortical, mid-brain and brainstem reticular formation
levels. The precise antipsychotic mechanism is not known.
The drug may also inhibit catecholamine receptors and
reuptake of various neurotransmitters in the mid-brain.
Haloperidol produces less sedation than phenothiazines,
with very little effect on heart rate, blood pressure, and res-
piration [44•]. A unique effect of haloperidol is a relatively
strong suppression of spontaneous musculoskeletal hyper-
activity and behavior that results from hyperdopaminergic
brain function, without pronounced sedation or hypoten-
sion. There appears to be a rather narrow range between
therapeutic doses for antipsychosis and the dose that pre-
cipitates extrapyramidal reactions. Currently, intravenous
dosage is not ‘approved’ by the US Food and Drug Admin-
istration, but the drug is commonly given by this mode, and
there has been a broad range of experience with it in the
peer-reviewed medical literature [45•,46•]. The dose and
frequency of administration is dependent on the degree of
agitation and, to a lesser extent, on the patient’s age.
Adverse hemodynamic effects from neuroleptics are rare in
healthy individuals [47,48]. Combined use of lorazepam and
haloperidol has been reported to be most effective in com-
bining antipsychotic effects and sedation, with a minimum of
side effects [49]. Haloperidol may be safer to use in
alcohol-related delirium than was previously thought [50].
One study [51] showed that haloperidol did not precipitate
any untoward side effects when used to treat a hetero-
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90 acutely alcohol-intoxicated patients. Tardive dystonia,
oculogyric crisis, torticollis, and trismus all occur rarely and
are mostly dose related. Neuroleptic malignant syndrome
may occur with any dose of haloperidol administration,
requiring ICU admission and aggressive, titrated life support.
Adjuvants to benzodiazepine sedation:
clonidine
In addition to its a-blockade actions, clonidine is an anxio-
lytic drug [52]. Clonidine is thought to act by competitively
binding opiate and catecholaminergic autoreceptors,
decreasing the amount of opiates required to achieve the
same sedative effect [53]. As a consequence, respiratory
depression, hypotension, and other side effects of nar-
cotic sedatives are significantly attenuated, especially in
hemodynamically unstable patients. Clonidine is almost
completely absorbed after oral administration, but takes
60–90 min to reach peak plasma concentration. Drug
delivery through a transdermal patch takes much longer to
achieve effective blood levels, and a minimum of 2 days to
achieve a steady-state concentration [54]. Transdermal
clonidine has been favorably compared with chlor-
diazepoxide in a double-blind randomized clinical trial of
the treatment of ethanol withdrawal [55]. Unfortunately,
clonidine is not yet approved for intravenous use in the
USA, but intravenous administration is common in Europe
and elsewhere [56].
Fentanyl: increasing benzodiazepine potency
Fentanyl is a synthetic opioid with morphine-like activity.
Fentanyl has a rapid onset of analgesic action ( 2–4 min),
short duration (30–40 min), and an often under-appreci-
ated sedative action as well [57]. Addition of the short-
acting analgesic fentanyl adds analgesia to the anxiolytic
action of midazolam, retains real-time titration ability for
about 48 h, and increases the clinical potency of both
drugs [58]. Fentanyl promotes less histamine release and
has significantly less effect on cardiac dynamics than mor-
phine. Fentanyl adds an accurately titratable analgesic and
sympatholytic effect to the anxiolytic effects of benzodi-
azepines, and is most effectively used in the continuous
infusion mode, because of its brief span of action [59].
The administration of fentanyl plus a benzodiazepine has
the potential to produce unexpected hypotension and res-
piratory depression [60]. Occasionally, the rapid adminis-
tration of high doses of fentanyl has resulted in muscular
and glotic rigidity during the induction of anesthesia. This
complication is reversible with naloxone [61]. Close hemo-
dynamic and ventilatory monitoring is indicated due to the
augmented potency of this combination.
Flumazenil: titrating sedation at the level of
neurotransmission
The administration of sedatives complicates the manage-
ment of ICU patients when the extent or duration of
sedation prevents assessments that require lucidity and
therapies that require patient cooperation. Examples
include the performance of neurologic examinations and
the measurement of effort-dependent weaning parameters
in patients undergoing mechanical ventilation. Moreover,
patients who are sedated for prolonged periods tend to
develop sedative accumulation throughout the various
body water compartments, leading to protracted lassitude
once drugs are removed from active infusion. Patients who
are sedated for prolonged periods suffer increased risk for
complications from immobility, such as deep venous
thrombosis, decubitus skin ulceration, and pressure-
induced peripheral neuropathy. It seems desirable to keep
patients sedated for the minimum time needed. The ability
to reverse sedation rapidly when it interferes with patient
care, or is no longer required, could improve the manage-
ment of a sizeable subgroup of ICU patients.
Flumazenil is an imidazobenzodiazepine that antagonizes
the effects of benzodiazepine agonists by competitive
interaction at the cerebral benzodiazepine receptor site
[62]. It does not antagonize the effects of other drugs that
do not affect benzodiazepine receptors, such as narcotics,
barbiturates, cyclic antidepressants, and ethanol. Because
benzodiazepines are frequently utilized for prolonged
sedation in ICUs, flumazenil may be useful for the titrated
reversal of sedation in this environment [63]. The recom-
mended initial dose of flumazenil, for the reversal of the
sedative effects of benzodiazepines administered for con-
scious sedation or general anesthesia, is 0.2mg adminis-
tered over 15 s [64]. It is important to remember, however,
that benzodiazepine effect can easily be reversed in a
smooth and titrated manner with a low-dose continuous
infusion of flumazenil, starting at 0.05mg/h and with con-
stant bedside observation of the effect [65•]. Slow and
progressive lightening up occurs, followed by progressive
resumption of quietude when the infusion is stopped.
Since it is a smooth transitional effect, ‘sudden awakening’
complications do not occur. Continuous infusion of
flumazenil may be efficacious for titrating the effect of
sedation at the level of their CNS receptor site, allowing
the practitioner further options for accurate control of
sedative agents.
Routes of drug administration
Oral administration of sedatives is problematic for agitated
patients because of erratic absorbtion and the complica-
tions that are inherent in placing nasogastric tubes for
drug administration. Intramuscular absorption of drugs is
influenced by the ratio of ionized to un-ionized drug, site of
injection, blood flow to the region, and amount of drug
metabolized before entry into the systemic circulation. All
of these variables are affected by critical illness. Intramus-
cular injection usually requires musculoskeletal activity and
adequate tissue perfusion to enhance absorption into the
systemic circulation. Because patients in the ICU gener-
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erratically. ICU patients also frequently suffer from
decreased tissue perfusion because of varying degrees of
heart failure and multiorgan insufficiency, as well as the
decreasing reliability of muscular absorption.
Intravenous administration of sedatives offers the advan-
tage of rapid onset and potent end-organ effect, very big
pluses in the treatment of unstable patients. Insertion of a
central venous catheter is usually indicated to ensure that
the drug continues to access the central circulation, as
peripheral intravenous infusions may infiltrate with very
little warning, particularly in the middle of the night. Intra-
arterial catheters are indicated for constant blood pres-
sure monitoring and easy access for blood sampling. Most
rapidly acting drugs are very lipid soluble and can only be
titrated by intravenous administration. The effective titrata-
bility of these drugs decreases with time, however, as the
volume of distribution throughout the body water compart-
ments increases. Organ insufficiency, particularly liver
failure, also decreases the short-term titratability of most
sedatives by prolonging the serum half-life.
Continuous infusions of analgesics and sedatives are a
very effective method for avoiding the bolus medication
therapies that initiate a ‘peak’ of therapeutic action fol-
lowed by a variable ‘valley’ period, during which the
patient receives little or no drug effect. Current literature
suggests that high-risk cardiac patients are jeopardized by
relatively brief periods of ineffective analgesia [66]. Inter-
mittent periods of sympathetic stimulation due to ineffec-
tive analgesia and sedation can cause relatively profound
deleterious effects on compromised myocardium [67].
Continuous intravenous infusions of short-acting agents
such as midazolam, propofol, and fentanyl allow titration of
plasma level effects to a fluctuating baseline of pain,
anxiety, and discomfort. This real-time titration of natural
fluctuations may occur with minimum hemodynamic and
respiratory suppression. Increased costs of newer short-
acting agents are justified if complications are avoided as
patients achieve more effective analgesia and sedation,
avoiding the blanket effects of less selective regimens.
Ethanol infusions
Although there is a paucity of evidence in the literature to
support it, intravenous 10% ethanol infusions have been
used for treating DT. On one level, this treatment is effec-
tive because it directly replaces the substance that is with-
drawn from the patient, resetting brain receptors with
equal potency. On other levels, however, this treatment
regimen is problematic. There is some evidence that
patients whose brain function is re-regulated with cross-
dependent substances such as benzodiazepines have a
stronger potential to choose sobriety after the detoxifica-
tion process. This is because the cross-dependent drugs
are not as euphoric and therefore less addictive than
ethanol. They become dependent on a more benign drug
that is easier to rehabilitate from. Ethanol is also a very
toxic drug to all organ systems, exacerbating gastric
bleeds, pancreatitis, and liver failure. There is no evidence
in the literature that ethanol infusions are any more effec-
tive than a thoughtful detoxification process using cross-
dependent sedatives in a carefully titrated care plan.
The ‘storm phase’ of delirium tremens
When the diagnosis is delayed for a considerable period
and the ‘storm phase’ is entered, it can be very difficult to
deal with DT because of cross-tolerance to cross-depen-
dent drugs such as benzodiazepines. Rapid changes from
restlessness to somnolesence necessitate the choice of a
drug with a rapid titratability, adjusting levels of sedation to
the prevalent state of CNS excitation. Propofol, a sedative–
anesthetic agent with a rapid onset and short duration of
action, appears to have a superior neuropharmaco-
dynamic profile in replacing actions of alcohol and alleviat-
ing the withdrawal symptomatology than barbiturates and
benzodiazepines, making it attractive as a substitute treat-
ment. Although the neuropharmacologic mechanism of
action of propofol has not yet been elucidated completely,
there is evidence suggesting that propofol may potentiate
GABA-evoked responses and may activate the GABA-A
receptors [68]. GABA-mediated presynaptic and post-
synaptic inhibition is believed to be related to the direct inter-
action of propofol with the GABA receptor complex [69].
Propofol appears to produce its inhibitory activity at both
spinal and supraspinal neuronal synapses [70]. It brings
about a dose-dependent diminution of cerebral blood
flow, decreases global cerebral metabolic rate, and is
potent enough to create a flat electroencephalogram in
high doses [71]. This state is rapidly reversible with no
neurologic change thereafter, which suggests that propo-
fol may provide cerebral protection. Potent general
depressant and anesthetic actions of propofol provide the
basis for the assumption that it produces these effects,
through its counteraction not only with GABA, but also
with the glutamate-gated ion channels. Therefore, the
pharmocodynamic profile of propofol appears to be supe-
rior to that of the benzodiazepines, approaching that of
ethanol, which makes it very advantageous in treatment of
the severe ethanol withdrawal states.
Propofol is a diisopropilphenol and is chemically related to
alcohols. Therefore, being an aromatic sedative–hypnotic
alcohol, it is believed to exhibit wider cross-dependence
with the neuropharmocodynamic profile of alcohol than do
conventional benzodiazepines or barbiturates. At the same
time, propofol appears to have different pharmacokinetics
and reduced cross-tolerance due to its predominant glu-
curonidation and excretion in the bile. This may allow
propofol to exert a more dramatic alleviating effect on
withdrawal symptomatology than benzodiazepines, which
Critical Care    Vol 4 No 2 Crippenshow a narrower spectrum of neuropharmacodynamic
effects. Propofol produces a progressive, dose-dependent
continuum of anxiolysis, hypnosis, sedation, and, finally,
anesthesia, which can be maintained by a rapidly
adjustable, titrated infusion. Propofol was compared with
midazolam with regard to its quality as a sedative agent,
and was found to be superior because of the significantly
shorter recovery time, improved titration during sedation,
reduced posthypnotic sleep, and faster weaning from
mechanical ventilation [72]. The lack of accumulation
allows the drug to be given by prolonged infusion. Some
clinical and experimental studies in which propofol has
been used for sedation and anesthesia [73] have revealed
cardiovascular depression. This phenomenon is believed
to be associated with both a mild negative inotropic effect
and a decrease in systemic vascular resistance, and is
especially evident in patients with hypovolemia and com-
promised cardiovascular status [74].
Delirium tremens and catecholamine storm
One of the therapeutic goals in the treatment of DT is to
avoid hemodynamic decompensation resulting from the
end-organ effect of catecholamine storm. Recent studies
suggest that decreasing stress-related tachycardia by the
use of super-selective, ultra-short-acting b-adrenergic
blocking agents may result in an aggregate benefit to
hemodynamics in heart failure by improving cardiac func-
tion by proportionally more than the small amount of nega-
tive inotropy inherent to the drug. The short duration and
rapid titratability of the short-acting b-adrenergic antago-
nist esmolol has been found to be advantageous to older,
longer-acting drugs in decreasing the adverse affects of
excessive tachycardia, increasing coronary artery blood
flow during diastole, and decreasing myocardial oxygen
consumption.
Several intravenous b-adrenergic antagonists are available
for use in the ICU. Atenolol is relatively water soluble,
incompletely absorbed, and cleared by the renal route,
and has a fairly long half-life [75]. Metoprolol is highly lipid
soluble, more completely absorbed, and cleared by the
hepatic route, and has a relatively short half-life [76].
Esmolol, a short-acting, rapidly titratable b-adrenergic
blocking agent has been demonstrated [77,78] to mani-
fest a preferentially negative chronotropic effect and can
be titrated by continuous infusion. The effects of hyperten-
sion with concomitant tachycardia can be safely resolved
using titrated intravenous infusions of labetalol, a drug that
manifests both a-adrenergic and b-adrenergic antagonis-
tic properties [79]. Labetalol can also be utilized in a con-
tinuous infusion, titrated in relatively brief intervals.
Cardiac function and fluid volume status can be accurately
monitored by pulmonary artery catheter and continuous
mixed venous oximetry, free from variations induced by
patient movement. Once the agitation syndrome runs its
course, hemodynamic and cerebral parameters will begin
to normalize, and therapy can be deintensified safely.
Delirium tremens: an acute intensive care unit
emergency
Escalating dosages of sedatives in the face of increasing
agitation is a genuine medical emergency that must be
dealt with aggressively. Therapeutic musculoskeletal
paralysis is frequently considered when the deleterious
side effects of sedation begin to pose a hemodynamic or
respiratory risk, and the patient’s neurobehavioral status is
still not controlled [80]. Hemodynamic deterioration from
the effects of agitation can precipitate angina, heart failure,
and cardiac arrhythmias by increasing myocardial work
and oxygen consumption in the face of a fixed coronary
artery output. If the severely agitated patient becomes
hypoxic and hypercapnic as a direct result of the effects of
agitation, therapeutic paralysis, intubation, and mechanical
ventilation will be necessary to reverse deleterious end-
organ effects [81]. Intentional therapeutic paralysis may
be complete or attenuated, allowing the patient some
movement but not unrestrained activity. Doses of neuro-
muscular relaxants may effectively be guided by peripheral
nerve stimulators according to protocol [82].
Suspended animation using musculoskeletal paralytic
agents will effectively stop increased oxygen consumption
and the effects of muscular hyperactivity on end organs. It
must be remembered, however, that underneath paralysis
lies a disordered cerebral function that is vulnerable to
damage from catecholamine storm and hemodynamic
instability. In the past, sedation has been titrated under
paralysis until tachycardia and hypertension normalize,
suggesting that patient comfort has been achieved. This is
a rough way of determining patient comfort under the
effects of paralysis, but the advent of cerebral function
monitoring has improved on this technique. To ensure that
the patient does not suffer a ‘buried alive’ sensation under
paralysis, it is highly preferable that sedation is tailored to
some objective assessment of real brain activity.
Once the patient is placed in suspended animation, many
end organs can be protected while specific therapeutics or
merely ‘tincture of time’ resolves the fundamental etiologies
of the agitation syndrome. Adverse effects of exogenous
catecholamines and endogenous neurotransmitters on the
brain can be blunted by titrating sedative, hypnotic, and
analgesic drugs to levels of cerebral electrical activity, as
monitored by cerebral function monitors in real-time. Cate-
cholamine storm and severe tachycardia causes a dramatic
increase in myocardial oxygen consumption, which can
lead to severe cardiac and hemodynamic complications.
Conclusion
Ethanol withdrawal was in the past considered a psychi-
atric disease. Detoxification was accomplished using
http://ccforum.com/content/4/2/081straitjackets, rubber rooms, and leather restraints. Today,
we recognize it as a potentially lethal process that requires
closely titrated care in a highly monitored setting, in which
normal and abnormal physiology can be appropriately
manipulated to the best interests of the patient. The aim of
short-term detoxification by the path of least resistance fol-
lowed by quick discharge, anticipating that the patient will
immediately resume drinking, is not realistic in a world in
which long-term goals are realistically attainable. ‘Detoxifi-
cation’ in a titrated manner in the ICU by establishing
cross-dependence puts patients in a position where they
are no longer as addicted to a euphoric yet toxic drug, and
eventual rehabilitation is thereby facilitated. This seems
like a noble and attainable goal for ICU care. Effective
treatment of ‘severe’ symptomatology requires aggressive
management. An indication to begin thinking about
aggressive treatment of cardiodynamics is the rapid esca-
lation of symptoms in the face of increasing sedation.
When sedation alone is insufficient, medication that is for-
mulated to lessen the effect of CNS sympathetic dis-
charge on end organs must be applied.
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